Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

(2018) Ines De Pauw et al.   Molecular Oncology

Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells

(2017) Muzafar A. Macha et al.   Oncotarget

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

(2016) P. M. Clement et al.   ANNALS OF ONCOLOGY

Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin

(2016) ROMAN C. BRANDS et al.   Molecular Medicine Reports

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma

(2016) Li Zhang et al.   Drug Design Development and Therapy

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

(2015) Jordi Giralt et al.   LANCET ONCOLOGY

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

(2015) Ricard Mesía et al.   LANCET ONCOLOGY

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib

(2015) Suresh Kumar et al.   Recent Patents on Anti-Cancer Drug Discovery

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

(2014) T. Y. Seiwert et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

(2014) K. Kian Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

(2014) Helmout Modjtahedi et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Afatinib: First Global Approval

(2013) Rosselle T. Dungo et al.   DRUGS

Differential effect of hypoxia on etoposide-induced DNA damage response and p53 regulation in different cell types

(2013) Audrey Sermeus et al.   JOURNAL OF CELLULAR PHYSIOLOGY

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

(2013) Nobuyuki Katakami et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study

(2013) Jean Louis Lefebvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment

(2013) Monique M. Nijkamp et al.   RADIOTHERAPY AND ONCOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

(2012) Mark Agulnik   MEDICAL ONCOLOGY

Resistance to EGFR-Targeted Therapy: A Family Affair

(2011) Gregory Vlacich et al.   CANCER CELL

Optimal treatment for recurrent/metastatic head and neck cancer

(2010) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) V. Gregoire et al.   ANNALS OF ONCOLOGY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity

(2008) Audrey Sermeus et al.   Molecular Cancer

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE